Rosa Therapeutics IncMonte Rosa Therapeutics Inc, founded in Basel in 2018, can look forward to an upfront payment of US$120m for its second collaboration and licensing deal with Novartis AG to develop protein degraders. A total of US$5.7bn is on the table for the new development of an anti-inflammatory candidate that is not part of Monte Rosa’s pipeline.
Tag Archive for: Deal
FRAXA Ewsearch OrganisationIn a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.
Sphingotec GmbHGerman diagnostics company Sphingotec GmbH has licensed its real-time kidney function test to US diagnostics giant Beckman Coulter allowing it to expand its business to the US as announced earlier this month.
Nxtera Pharma LtdNxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
Lipid, nutrition and frozen bakery specialist Allianza Team puts £900,500 into pre-Series A financing of microbial palm oil producer Clean Food Group Ltd.
TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
Mithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada.
siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T